Optogenetic Actuators & Sensors Market Worth $584.73 Million By 2025

The global optogenetics actuators & sensors market size is expected to reach USD 584.73 million by 2025, according to a new report by Grand View Research, Inc., exhibiting a 1.93% CAGR during the forecast period. Extensive research in the field of neuroscience and ophthalmology is expected to boost the market growth in the coming years. Key players are focusing majorly on research activities to study brain functions in various psychiatric and retinal disease states, which is anticipated to drive the sector.

Government organizations are providing funds to academic research institutions and individual researchers for advancements in the field of optogenetics. Moreover, various initiatives undertaken by international organizations such as WHO and NIH are anticipated to boost the market growth. Various projects and initiatives initiated in the field of neuroscience are also promoting growth prospects.

In addition, ongoing investigations to improve signal sizes and responses and target specificity of subcellular membranes such as axon terminals, cell bodies, and dendrites in neuroscience are expected to support the growth of the segment. Rise in incidence of retinal and brain disorders are ultimately increasing demand for optogenetic actuators and sensors.

Furthermore, changing healthcare reforms and public-private collaborations among industrial players, government, and research institutions are expected to drive technological progressions in optogenetics. This, in turn, is anticipated to significantly boost the growth of the optogenetics actuators and sensors market over the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/optogenetics-actuators-sensors-market

Further Key Findings From the Report Suggest:

Actuators are estimated to account for the largest revenue share owing to their increased usage in investigations related to neuroscience and ophthalmology
Sensors are anticipated to grow at the fastest rate in the coming years due to technological advancements in optogenetics
Retinal disorders accounted for the largest revenue share owing to higher usage of optogenetic actuators and sensors in disease-oriented studies. Rise in prevalence of various retinal and psychiatric disorders is also anticipated to boost the segment
North America dominated the market owing to government support, extensive research, local presence of a substantial number of players, and well-established healthcare framework
Asia Pacific is expected to exhibit the fastest growth over the forecast period owing to progressive industrialization and favorable government support
Major players include Bruker; Circuit Therapeutics, Inc.; Gensight Biologics; AGTC; Prizmatix; Merck KGaA; Elliot Scientific Ltd; Coherent, Inc.; The Jackson Laboratory; Scientifica (Judges Scientific Plc Company); Addgene; Shanghai Laser & Optics Century Co., Ltd. (SLOC); Noldus Information Technology; Thorlabs, Inc.; and Danaher
Companies are collaborating with academic institutions and private and public entities to accelerate developments in optogenetics.

Liquid Biopsy Market Size Worth $5.96 Billion By 2030

The global liquid biopsy market size is expected to reach USD 5.96 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 13.4% during the forecast period. Enhanced view of tumor provided by liquid biopsy technology is estimated to augment the market in coming years.

While tissue biopsies have been standard for cancer diagnosis for past several year, their highly invasive nature and frequently associated complications have been major concerns. Moreover, these biopsies lead to high expenditure being incurred by patients. Liquid biopsies, on the other hand, offer a less invasive methodology along with high effectiveness. Thus, there are a number of key private organizations involved in rigorous R&D activities for liquid biopsy test development and it is only a matter of time before these procedures grow in prominence in diagnostic paraphernalia of oncologists and pathologists.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market

Further key findings from the report suggest:

Technological developments such as electric field induced release and measurement (EFIRM)- Liquid Biopsy (eLB), which provides detection that can assist clinical treatment decisions for most common subtype of cancers are expected to drive the uptake of saliva based sampling over the forecast period
Currently, clinical use of isolation and detection technology is limited to CTC quantitation but the number of CTCs is found to hold significant correlation with disease severity. This is, thus, estimated to augment the market over the coming years
Rising awareness regarding advantages of multiple gene analysis along with the help of NGS is anticipated to support the growth of the market
Organizations such as American Society of Clinical Oncology (ASCO) are engaged in supporting implementation of liquid biopsy, which in turn is likely to spur the growth of the market
Intensifying competition between biotech companies and increasing investments by government in healthcare institutes will lead to development of more sophisticated tests
Companies engaged in R&D and commercialization of these products include Pathway Genomics; Natera Inc.; Epic Sciences; Illumina; Foundation Medicine; Roche; LabCorp; and Sequenom

Viral Vectors & Plasmid DNA Manufacturing Market Worth $1.1 Billion By 2027

The global viral vectors & plasmid DNA manufacturing market size is expected to reach USD 1.1 billion by 2027, exhibiting a 14.52% CAGR, during the forecast period, according to a new report by Grand View Research, Inc. Currently, more than 700 cell and gene therapies are in clinical trials and vectors are used in nearly 70% of these therapies. As a result, demand for vectors has exceeded the supply rate. Thus, an increase in the number of advanced therapy-based discovery programs initiated by biotechnology and pharmaceutical companies is expected to drive investments in the market.

Current production methods for viral vectors are considered tedious, as they are only applicable for scale-out but not for scale-up. Development of a proprietary CAP-GT technology-based cell suspension system by CEVEC Pharmaceuticals GmbH has effectively addressed the challenge of scaling-up by allowing easy handling and improved efficiency of cells.

Considering growing opportunities in vector production, the Original Equipment Manufacturers (OEMs) are making focused efforts to gain a competitive advantage in the market. For example, the introduction of ready-to-run factory-in-a-box to accelerate the production of virus-based therapeutics by GE healthcare, as a solution to simplify and advance the manufacturing process.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/viral-vector-manufacturing-market

Further key findings from the study suggest:

With high usage, attributed to its ability of high titer production and capability to induce strong humoral and T cell responses in various research applications, adenovirus held the leading viral vectors and plasmid DNA manufacturing market share in terms of revenue, in 2019
Lentivirus vector is anticipated to register the fastest CAGR over the forecast period. This can be attributed to constant growth in the lentivirus-based gene therapy pipeline program
Downstream processing held the dominant revenue share in 2019, owing to the fact that this process involves purification steps that account for the majority of the overall manufacturing cost. Employment of expensive equipment and requirement of trained personnel for product recovery has further driven revenue in the segment
Antisense and RNAi therapy production is estimated as the key application of vector manufacturing, resulting in the dominance of this segment over other applications
The high adoption rate of viruses for aptamers and oligonucleotide development in comparison to other applications has driven revenue in antisense and RNAi therapy segment
High usage of vectors for therapeutic production have contributed to the large revenue share of pharmaceutical and biopharmaceutical companies. The number of biotech companies employing vector for therapies production is anticipated to multiply over the forecast period
Presence of a substantial number of advanced therapy products in the pipeline targeting various cancer forms has accelerated revenue share of the cancer segment over the years
Given the high number of biotech entities in parts of U.S., such as in California and Massachusetts, North America has maintained its dominance in terms of revenue. In addition, the active participation of regulatory bodies in improving the regulatory scenario for the market launch of advanced therapies has facilitated the high usage of vectors in U.S.
Merck, Cobra Biologics, Novasep, and uniQure N.V., are some key participants that are geared towards capitalizing the untapped opportunities in the market

Molecular Cytogenetics Market Size Worth $3.8 Billion By 2025

The global molecular cytogenetics market size is expected to reach USD 3. 8 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a 10.4% CAGR during the forecast period. Mapping of human genome, coupled with continuous technological advancements in cytogenetic techniques, has enabled researchers to gain insight into the disease-causing mechanism at a genomic as well as the cellular level. Development in molecular technologies has helped in bridging the gap between molecular biology and cytogenetics, which was not possible using conventional cytogenetic techniques.

There is a continuous growth in awareness, and consequent adoption, of genetic tests for disease prognosis. These tests also help in designing further treatment regimes for widespread chromosomal abnormalities. This is sure to boost the market growth.

Incorporation of high throughput sequencers in the cytogenetic analysis is expected to significantly enhance the market growth in the coming years. A number of researchers and scientists have begun converging cytogenetics laboratories with NGS as they complement each other. Hence, with an exponential decline in sequencing prices, this market is expected to grow at a lucrative pace.

However, ambiguous regulatory and reimbursement scenario in certain regions pertaining to the implementation of genetic tests is expected to hamper the adoption of molecular cytogenetic techniques to a certain extent.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/molecular-cytogenetics-market

Further key findings from the report suggest:

Oncology held the largest share in the market in 2016 owing to the ability of CGH technology to facilitate in-depth studies for cancer etiology
The use of molecular cytogenetics in personalized medicine development is expected to grow lucratively during the forecast period. This is majorly due to a continuous shift toward targeted therapies for effective disease management
The requirement of consumables in the entire cytogenetics process is attributive for the largest share of this product category
Ongoing research projects for developing a treatment regimen of different genetic conditions have allowed clinical and research laboratories to gain a significant share in the market
Pharmaceutical and biotech companies are expected to be a key source of revenue in the coming years. This is mainly because a number of pharmaceutical companies have expanded their business in the field of personalized medicine
Illumina, Inc.; Agilent Technologies, Inc.; Abbott; Bio-Rad Laboratories, Inc.; and Oxford Gene Technology are some prominent companies in the market. They are involved in the development and commercialization of cytogenetics techniques
Some major service providers are Weill Cornell Medicine; WiCell Research Institute, Inc.; ARUP Laboratories; and Integrated Systems Engineering S.r.l.

Latin America In Vitro Diagnostics Market Size To Reach $5.1 Billion By 2024

The latin america IVD market is expected to reach over USD 5.1 billion by 2024, according to a new report by Grand View Research, Inc. The Latin America IVD market is expected to grow at a significant CAGR till 2024 owing to the rising prevalence of target disorders, aging population, and the presence of favorable government initiatives for early disease diagnosis. Other factors that are anticipated to boost the growth include the introduction of technologically advanced instruments and the increasing R&D initiatives for the development of disease-specific kits.

Regular testing for diabetes, cardiovascular, cancer, and sexually transmitted diseases are necessary for the timely treatments, further avoiding the risk of fatal health complications. The availability of tests for home and near patient testing is estimated to further enhance the usage rates of these devices. From November 2015, the Anvisa, which is a regulatory body for medical devices in Brazil, has started allowing the registration for HIV self-testing kits.

The increasing adoption point of care devices coupled with the increasing awareness among the healthcare professionals regarding the early diagnosis of various diseases has provided a boost to the Latin IVD market. The rising epidemic of communicable diseases in the southernpart of Latin America, the growing need for rapid and accurate diagnostics, and the changing healthcare infrastructure scenario are some of the key drivers of the Latin IVD market.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/latin-america-in-vitro-diagnostics-ivd-market

Further key findings from the study suggest:

The instrument segment is one of the most important segments of in vitro diagnostics. The presence of highly automated analyzers and the availability of over the counter products are some of the factors responsible for its significant share.
The Molecular diagnostics segment is anticipated to be the fastest growing technology over the decade. Molecular diagnostics is a transformative area of diagnostics. The continuous innovation in technology helps the physicians for critical decision making
The infectious disease segment held the largest share in 2015 over 24% owing to the presence of favorable government initiatives in association with the WHO to curb communicable diseases.
The home care segment is estimated to witness a significant growth over the forecast period. The high number of R&D initiatives undertaken by key competitors for the development of portable IVD devices with improved sensitivity and user-friendliness is a key factor attributing towards its growth.
In 2015, Brazil was the largest regional segment with a revenue generation of over USD 1.2 billion owing to the established healthcare infrastructure, growing awareness for cancer screening, and the increasing demand for genetic testing.
Peru is expected to be one of the fastest growing regions on account of the growing economic stability, high unmet clinical needs, and the rising disposable incomes
Key players operating in the Latin America IVD market are Roche Diagnostics, Abbott Laboratories, Inc., Hologic (Gen-Probe), Becton Dickinson (BD) Company, Alere, Inc., Bio-Rad Laboratories, Qiagen N.V., Inc., bioMerieux, BioQuidel Corporation, and Siemens Healthcare.

Oligonucleotide Synthesis Market Size Worth $3.9 Billion By 2025

The global oligonucleotide synthesis market size is expected to reach USD 3.9 billion by 2025 at a 12.4% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Continuous rise in usage of oligonucleotide synthesis across various aspects of human health management, from molecular diagnostics to therapeutics, is spurring revenue growth.

The recent success of oligonucleotide-based drugs in medicine due to increase in number of FDA-approved products is anticipated to boost revenue generation in this market. As of September 2017, there are six approved oligonucleotide therapeutic products.

A substantial number of oligos are being investigated for their usage in targeting various infectious diseases. For instance, dsDNA thioaptamers are reported to target the ribonuclease H (RNase H) domain of HIV-RT and are demonstrated to inhibit HIV-RT when used in vitro.

In addition, demand for cancer-related thioapatmers that can detect presence as well as target tumor growth factors, such as TGF-β, is on a continuous rise. This, in turn, has led to increase in investments for exploring the significance of custom oligonucleotide synthesis in cancer research.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/oligonucleotide-synthesis-market

Further key findings from the report suggest:

Growing usage of ready as well as custom oligos in genomic research is expected to drive the market
Column-based oligos have a higher per nucleotide base price compared to array-based oligos. As a result, column-based oligos accounted for the largest revenue share by product type in 2017
North America dominated the global market in 2017 as a result of large investments in genetic research and effective regulatory policies that encourage gene-based research activities in the region
Asian countries are expected to emerge as a key source of lucrative revenue generation during the forecast period. This is primarily due to growing awareness as well as popularity of genetic medicine among the population
The market is highly fragmented, with the presence of several major and emerging players offering DNAs, RNAs, and other oligos. Market competition is anticipated to increase with growing number of new entrants offering customized services
Some of the key companies in the market are BioAutomation; Integrated DNA Technologies, Inc.; LGC Biosearch Technologies; Agilent Technologies; GE Healthcare Dharmacon Inc.; and Gene Scripts.

Single-Cell Genome Sequencing Market Worth $2.5 Billion By 2025

The global single-cell genome sequencing market size is expected to reach USD 2.49 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 14.64% during the forecast period. Advancements in the field of single-cell analysis are anticipated to boost the growth of the market in the coming years.

Moreover, active participation and contribution of market players toward product upgradation are playing an important role in the growth of the market. Increasing number of collaborations and strategic alliances between companies are fostering the development of a collaborative portfolio in the system.

Moreover, emergence of next-generation sequencing (NGS) has helped the market gain tremendous traction over the past few years. Earlier, single-cell genome sequencing market was dominated by PCR and microarray technologies. However, qPCR and NGS are increasingly emerging as the preferred technologies.

Furthermore, rising number of single-cell genome sequencing centers & associated facilities worldwide is fostering growth prospects. The main objective of such entities is to develop novel single-cell genome sequencing-based applications and methods. These centers are also playing a major role in introducing advanced tools & instruments for scientific communities of various regions. This, in turn, is helping augmenting growth opportunities for the market.

In addition, public-private collaborations among governments, companies, and research institutions in the space are expected to promote more research initiatives. Various funding grants by NIH and private players such as Mission Bio are escalating the growth of the market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/single-cell-genome-sequencing-market

Further Key Findings From the Report Suggest:

Instruments are estimated to account for the leading share in the market throughout the forecast period owing to optimal availability of products for single-cell sequencing kits. The segment is poised to command about 58.0% of the overall revenue
NGS (Next-Generation Sequencing) is the most promising technology segment owing to the launch of integrated & advanced platforms for single-cell analysis. The segment is projected to expand at a CAGR of 15.72% during the forecast period
Circulating cells will hold the largest share throughout the forecast period owing to intensive research studies on circulating tumor cells in the area of cancer progressions and treatment
Academic & research laboratories will be the dominant revenue contributor during the same period. The dominance can be attributed to presence of established genomic centers and their research initiatives in the space
North America dominated the market owing to well-established administration support, investigations, and presence of substantial number of regional players
Asia Pacific region is expected to exhibit the fastest growth over the forecast period owing to active participation of players, extensive research, and favorable government support
Major players include F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific, Inc.; QIAGEN; Bio-Rad Laboratories; 10x Genomics; Novogene; Fludigim; BGI; Illumina, Inc.; Oxford Nanopore Technologies; and Pacific Biosciences. Companies are collaborating with private & public entities as well as academic institutions to accelerate advancements in the single-cell genome sequencing market.

Antibody Production Market Worth $22.6 Billion By 2025

The global antibody production market size is expected to reach a value of USD 22.6 billion by 2025, at a CAGR of 13.5% according to a new report by Grand View Research, Inc. Increasing demand for therapeutic antibodies including monoclonal and polyclonal antibodies is a major factor that drives the growth of the market during the forecast period. Antibodies are the dominant biopharmaceuticals that specifically target the abnormal cells. Thus, many pharmaceuticals and biotechnology companies have begun to focus on the development of advanced antibodies for the treatment of chronic diseases such as cancer, rheumatic heart disease, and arthritis.

Patent expiry of several blockbuster monoclonal antibodies in the near future is another major factor supporting market growth. Several antibodies such as Avastin, Herceptin, and Mabthera are going to lose their patents in a few years. For instance, the patent of Herceptin (trastuzumab) expired in Europe in July 2014 and will expire in the U.S. in June 2019. Many companies such as Amgen Inc., Synthon, Biocon, and Pfizer Inc. are developing biosimilar for trastuzumab, which is expected to propel the demand for antibody production products.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/antibody-production-market

Further key findings from the study suggest:

Downstream processing was the largest revenue-grossing segment of the antibody production market in 2016. It is also expected to exhibit the highest CAGR during the forecast period, owing to the large application of chromatography devices and resins in downstream processing
The monoclonal antibody segment was leading in 2016, due to its higher demand in treatment of chronic diseases including cancer, blood disorders, and growth hormone deficiency
The pharmaceutical and biotechnology companies segment dominated the overall market in terms of revenue in 2016, owing to the large production of therapeutic antibodies and high investment in R&D by companies for drug development
North America was the largest revenue-generating region of the market in the year 2016. This region is expected to maintain its position during the forecast period because of the presence of several leading biopharmaceuticals and biotechnology companies in this region
Asia Pacific region is projected to be the fastest-growing segment over the study period, due to rapidly booming biotechnology industry and comparatively less stringent regulations for biologics development in APAC region
Some of the key players include GE Healthcare; Thermo Fisher Scientific, Inc.; Sartorius AG; Merck KGaA; Pall Corp.; Eppendorf AG; Cellab GmbH; INTEGRA Biosciences AG; and FiberCell Systems Inc.

Cell Harvesting System Market Size Worth $10.17 Billion By 2025

The global cell harvesting system market is expected to reach USD 10.17 billion by 2025, according to a new report by Grand View Research, Inc. The increasing demand for stem cell-based therapies, owing to the growing base of aging population and increasing prevalence of chronic diseases, is one of the major factors contributing toward lucrative market growth.

Growing investment in stem cell research is one of the high impact rendering drivers contributing to the demand for stem cells, which thereby contributes to the growth of the cell harvesting system market. There has been a significant rise in the stem cell transplantation rate globally, which is another major driver for increasing demand across the globe. Growth in autologous stem cell transplantation along with increasing stem cell banking is stimulating demand for cell harvesting system.

The potential use of stem cells in regenerative medicine, such as in the case of cancer, trauma, congenital diseases, etc., is also one of the factors contributing to the demand for stem cells for research, thereby contributing toward the growth of cell harvesting system market across the globe. The rising prevalence of certain diseases such as cancer is expected to drive the growth of this market over the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cell-harvesting-systems-market

Further key findings from the report suggest:

Umbilical cord, bone marrow, peripheral blood, adipose tissue, and other sources are the application segments analyzed in this study. Peripheral blood dominates the application market and is expected to do maintain its dominance over the forecast period.
Hospitals held the largest share in the end-use segment and is expected to hold the largest share over the forecast period, as a majority of stem cell harvesting for transplantation and banking is done in hospitals. Rise in stem cell research is expected to contribute to the growth of stem cell harvesting in academic institutes and R&D centers.
North America and Europe dominated the cell harvesting system market owing to the high rate of stem cell transplantation and research. Aging population and rising prevalence of cancer are further expected to contribute to the growth of the market in these regions.
Some of the key players are Argos Technologies, Inc.; Perkin Elmer, Inc.; Brand GmBh + CO KG; Arthrex, Inc.; Avita Medical; Tomtec; Terumo Corporation; Teleflex, Inc.; and Bertin Technologies.

Protein Labeling Market Size Worth $2.60 Billion By 2024

The global protein labeling market size is expected to reach USD 2.60 billion by 2024, according to a new report by Grand View Research, Inc., registering a CAGR of 9.3% during the forecast period. Development and commercial launch of high accuracy and rapid labeling products is expected to enhance market growth.

Post-translation Modification (PTM) such as proteolysis, lipidation, acetylation, methylation, nitrosylation, ubiquitination, glycosylation, and phosphorylation influence all aspects of pathogenesis as well as normal cell functioning. PTM studies are rapidly being adopted to investigate biological functions of various proteins and their role in disease prognosis.

Availability of a broad range of labels for covalent attachment of different molecules provides researchers the choice to select labels to suit specific applications. Fluorescent labeling does not require additional reagents for protein detection due to its ability to respond to light signals. This ability of fluorescence molecules has significantly contributed to its rapid adoption in in vivo protein labeling.

High R&D spending to reduce complexity in protein labeling and increased adoption of sophisticated bioengineering techniques in various sectors of biotechnology further contribute to market growth. Development of rapid diagnostic tests based on detection of the presence of specific protein proves to be of great significance for rapid and cost-effective diagnostics. Focus on development of advanced diagnostic tests based on protein detection is expected to fuel new product development.

Technological advancements in genetic sequencing methodologies has drastically reduced the cost of genome profiling. This is expected to drive demand for protein expression analysis, which is the next step in genetic analysis after sequencing. Declining sequencing cost has increased the number of proteomic and genomic profiling studies, which is projected to fuel demand for protein labeling over the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/protein-labeling-market

Further key findings from the report suggest:

Rapid adoption of post-translational modification studies in proteomics is expected to fuel demand for reagents
SNAP-, CLIP-, MCP-, and ACP- tags are some of the fusion proteins used for covalent labeling. Ability to provide irreversible covalent labeling and labeling for membrane protein drives demand for probes/tags in labeling
Demand for kits for clinical diagnosis of various diseases based on protein detection fuels the kits product segment
North America dominated the market due to presence of key players and high investments in proteomics research. Canada is poised to witness lucrative growth owing to increasing number of research projects focused on improving healthcare solutions
Europe is a key regional market. The Seventh Framework Program of the European Union provided funds for P-CUBE – an infrastructure for Protein Production Platforms to provide access to most advanced techniques to researchers
Asia Pacific is expected to observe remarkable growth over the forecast period, especially in China and Japan
Major companies operating in the market include F. Hoffmann-La Roche AG; GE Healthcare Life Science; Promega Corporation; PerkinElmer Inc.; Merck Millipore; Thermo Fisher Scientific Inc.; Kirkegaard & Perry Laboratories (KPL); Eurogentec S.A.; New England Biolabs; and LI-COR Inc.
Key players are involved in acquisition of smaller players and are expanding their product portfolio, resulting in market consolidation.